Genetic medicine: the next generation
A new report from Evaluate Vantage looks at new approaches aiming to solve problems facing the current generation of genetic medicines.
Amylyx faces an uphill battle
Briefing documents show why the FDA should await more data on the ALS project, but will it bow to patient pressure?
The year the regulators meet the microbiome
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
Licensing deals rack up in 2021
This year has yet to see a blockbuster-style deal, but prices remain punchy nevertheless.
A radical strategy for Medtronic
The sellside expects the world’s leading medtech to be outpaced by its rivals. Divestments might allow the group to defy this destiny.
Atea’s woes grow while other Covid readouts approach
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.
A remyelinating agent remains a distant hope
But the pipeline contains various approaches that are worth watching, with data from Abbvie possibly the next big event.
The heat is on for Oxford Nanopore
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
